- Home
- KLTOW vs HPS Comparison
KLTOW vs HPS Comparison
Compare KLTOW & HPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTOW
- HPS
- Stock Information
- Founded
- KLTOW N/A
- HPS 2003
- Country
- KLTOW United States
- HPS United States
- Employees
- KLTOW 3
- HPS N/A
- Industry
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- HPS Investment Managers
- Sector
- KLTOW Health Care
- HPS Finance
- Exchange
- KLTOW Nasdaq
- HPS Nasdaq
- Market Cap
- KLTOW N/A
- HPS 450.7M
- IPO Year
- KLTOW 2022
- HPS N/A
- Fundamental
- Price
- KLTOW $0.24
- HPS $14.47
- Analyst Decision
- KLTOW
- HPS
- Analyst Count
- KLTOW 0
- HPS 0
- Target Price
- KLTOW N/A
- HPS N/A
- AVG Volume (30 Days)
- KLTOW N/A
- HPS 58.4K
- Earning Date
- KLTOW N/A
- HPS 01-01-0001
- Dividend Yield
- KLTOW N/A
- HPS 8.62%
- EPS Growth
- KLTOW N/A
- HPS N/A
- EPS
- KLTOW N/A
- HPS N/A
- Revenue
- KLTOW N/A
- HPS N/A
- Revenue This Year
- KLTOW N/A
- HPS N/A
- Revenue Next Year
- KLTOW N/A
- HPS N/A
- P/E Ratio
- KLTOW N/A
- HPS N/A
- Revenue Growth
- KLTOW N/A
- HPS N/A
- 52 Week Low
- KLTOW N/A
- HPS $11.79
- 52 Week High
- KLTOW N/A
- HPS $15.40
- Technical
- Relative Strength Index (RSI)
- KLTOW N/A
- HPS 63.97
- Support Level
- KLTOW N/A
- HPS $14.17
- Resistance Level
- KLTOW N/A
- HPS $14.20
- Average True Range (ATR)
- KLTOW 0.00
- HPS 0.13
- MACD
- KLTOW 0.00
- HPS 0.04
- Stochastic Oscillator
- KLTOW 0.00
- HPS 93.62
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.